文献速递关节外科

高风险患者继续使用75mg阿司匹林与健康患者使用低分子肝素相比不增加静脉血栓栓塞风险

No Increased Risk of Venous Thromboembolism in High-Risk Patients Continuing Their Dose of 75 mg Aspirin Compared to Healthier Patients Given Low-Molecular-Weight Heparin.
PubMed 文献 · J Arthroplasty · 2021-06-10

这项前瞻性观察研究纳入2014至2020年全髋或全膝关节置换术患者,比较已服用阿司匹林75mg的心血管病高风险患者与使用低分子肝素的患者。结果显示两组在深静脉血栓、肺栓塞、深部感染、输血和死亡方面均无统计学显著差异,提示阿司匹林75mg用于VTE预防是安全的。

要点

  • 阿司匹林组与低分子肝素组的DVT和PE发生率无显著差异。
  • 两组在深部感染、异体输血和死亡率方面也无差异。
  • 阿司匹林75mg每日一次可用于全髋或全膝关节置换术后VTE预防。

核心结论

  • 阿司匹林75mg与低分子肝素用于VTE预防时并发症发生率无统计学显著差异。
  • 阿司匹林75mg每日一次在全髋或全膝关节置换术后用于VTE预防是安全的。

研究设计与样本

  • 前瞻性观察研究,纳入2014至2020年所有全髋或全膝关节置换术患者。
  • 两组均包括初次或翻修全髋或全膝关节置换术患者。
  • 阿司匹林组年龄更大(73 ± 7.8岁 vs 66 ± 10.2岁,P < .01,95% CI -7.6, -6.3)且合并症更多,其他方面与低分子肝素组无差异。

主要发现

  • 阿司匹林组深静脉血栓发生率为0.28%,肺栓塞发生率为0.28%。
  • 低分子肝素组深静脉血栓发生率为0.24%,肺栓塞发生率为0.16%(P = .42和.74)。
  • 两组在深部感染、异体输血或死亡率方面无差异。

关键数值与推荐

  • 阿司匹林组DVT 0.28%,PE 0.28%;低分子肝素组DVT 0.24%,PE 0.16%(P = .42和.74)。
  • 结局指标在3个月随访时记录,包括临床深静脉血栓、肺栓塞、深部感染、输血和死亡。

临床怎么用

  • 对于已因心血管疾病服用阿司匹林75mg的患者,全髋或全膝关节置换术后可继续每日服用作为VTE预防。
  • 阿司匹林75mg每日一次可作为全髋或全膝关节置换术后VTE预防的安全选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Optimum venous thromboembolism (VTE) prophylaxis for patients undergoing total hip or knee arthroplasty remains undefined. The purpose of this study is to compare complication rates among total joint arthroplasty patients using either low-dose aspirin (75 mg once daily) or low-molecular-weight heparin (LMWH; Fragmin/dalteparin 5000 U) for VTE prophylaxis. METHODS: This is a prospective observational study. All total hip or knee arthroplasties from 2014 to 2020 were included. One thousand eighty-four patients already taking aspirin 75 mg as primary or secondary prophylaxis for cardiovascular disease continued their daily aspirin dose throughout their hospital stay and after discharge without any other kind of thromboprophylaxis. Five thousand ten patients not already taking aspirin were given LMWH for 12-14 days starting the day of surgery. Both groups consisted of patients undergoing either primary or revision total hip or knee arthroplasty. The aspirin group was older (73 ± 7.8 vs 66 ± 10.2 years, P < .01, 95% CI -7.6, -6.3) with more comorbidities but otherwise did not differ from the LMWH group. Outcome measures were recorded at 3-month follow-up and included the following complications: clinically deep venous thrombosis (DVT), pulmonary embolism (PE), deep infection, blood transfusion, and death. RESULTS: The aspirin group had 0.28% DVT and 0.28% PE, and the LMWH group had 0.24% DVT and 0.16% PE (P = .42 and .74, respectively). No difference in deep infection, allogenic blood transfusion, or mortality was found. CONCLUSION: No statistically significant difference in complication rates was found between aspirin 75 mg and LMWH used for VTE prophylaxis. Aspirin 75 mg daily is safe for VTE prophylaxis after total hip or knee arthroplasty.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Hovik O, Amlie EJ, Jenssen KK, et al. No Increased Risk of Venous Thromboembolism in High-Risk Patients Continuing Their Dose of 75 mg Aspirin Compared to Healthier Patients Given Low-Molecular-Weight Heparin. J Arthroplasty. 2021. PMID: 34176693. doi:10.1016/j.arth.2021.06.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。